Therefore, we used an established MYBL2 gene signature (26) to identify and nominate candidate drug targets as a novel therapeutic direction using the cancer therapeutics response portal for patients with prostate cancer with overexpression of MYBL2 and/or increased MYBL2 activity (Fig. 5C). Here, MYBL2 is linked to cancer.